Privi Speciality Chemicals gets USFDA certificate for camphor product

The company can now expand its business horizon into the area of pharmaceutical applications in the USA

USFDA completes inspection at Biocon Biologics’ Insulins facility at Malaysia

The inspection concluded with the issuance of a form 483 with five observations

USFDA inspection update on Jubilant HollisterStier’s Montreal facility

HSGP is engaged closely with the USFDA and is committed to address the OAI observations through planned remediation measures

Department of Pharmaceuticals continues with special campaign for disposal of pending matters

Target identification will commence on 17 September 2024, following the timeline provided in the campaign guidelines

Ayush Ministry resolves 1346 Public Grievances under the Special Campaign 3.0

Secretary Vaidya Rajesh Kotecha has urged senior officials to strive for the successful attainment of targets during the campaign

USFDA determines inspection classification of VAI for the contract manufacturing facility at Spokane, Washington

Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding

Granules India’s Gagillapur facility completes USFDA inspection with six observations

The recent inspection covered both cGMP and PAI processes

Suspected Mpox case under investigation

The patient has been isolated in a designated hospital and is currently stable

ANVISA completes inspection at Caplin Steriles' facility at Gummidipoondi

Zydus Lifesciences to scale up US specialties business

The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US